We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes Presents Phase III Data on Schizophrenia Candidate
Read MoreHide Full Article
Alkermes plc (ALKS - Free Report) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831. It is a supportive study in the broad clinical development program, ENLIGTHEN on ALKS 3831.
We note that ALKS 3831 is a once-daily, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia.
Alkermes’ share price increased 4.3% year to date, underperforming the Zacks classified Medical - Biomedical and Genetics industry’s gain of 6.4%.
ENLIGHTEN-1 study is assessing the antipsychotic efficacy of ALKS 3831 compared with placebo over four weeks in patients with acute exacerbation of schizophrenia. The study also includes a comparator arm of Eli Lilly and Company’s (LLY - Free Report) Zyprexa (olanzapine), an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain.
The study met its primary endpoint, demonstrating statistically significant reductions in Positive and Negative Syndrome Scale (PANSS) scores versus placebo from the baseline. The candidate showed improvements similar to Zyprexa.
Moreover, ALKS 3831 showed similar weight gain and metabolic side effects commonly associated with the use of Zyprexa.
The company is conducting another phase III study, ENLIGHTEN-2, evaluating weight gain with ALKS 3831 compared with Zyprexda. The data from the study is expected in 2018. A favorable weight and metabolic profile compared to Zyprexa will make the candidate a potential treatment for schizophrenia.
Per the press release, the chronic, severe and disabling brain disorder, schizophrenia affects approximately 2.4 million adults in the U.S.
We note that the market for schizophrenia is highly competitive with the presence of drugs from large-cap pharma companies including Johnson & Johnson’s (JNJ - Free Report) Invega Sustenna and Risperdal Consta, and Allergan plc’s Vraylar. A few other companies are also developing their candidates for this indication.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Alkermes Presents Phase III Data on Schizophrenia Candidate
Alkermes plc (ALKS - Free Report) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831. It is a supportive study in the broad clinical development program, ENLIGTHEN on ALKS 3831.
We note that ALKS 3831 is a once-daily, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia.
Alkermes’ share price increased 4.3% year to date, underperforming the Zacks classified Medical - Biomedical and Genetics industry’s gain of 6.4%.
ENLIGHTEN-1 study is assessing the antipsychotic efficacy of ALKS 3831 compared with placebo over four weeks in patients with acute exacerbation of schizophrenia. The study also includes a comparator arm of Eli Lilly and Company’s (LLY - Free Report) Zyprexa (olanzapine), an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain.
The study met its primary endpoint, demonstrating statistically significant reductions in Positive and Negative Syndrome Scale (PANSS) scores versus placebo from the baseline. The candidate showed improvements similar to Zyprexa.
Moreover, ALKS 3831 showed similar weight gain and metabolic side effects commonly associated with the use of Zyprexa.
The company is conducting another phase III study, ENLIGHTEN-2, evaluating weight gain with ALKS 3831 compared with Zyprexda. The data from the study is expected in 2018. A favorable weight and metabolic profile compared to Zyprexa will make the candidate a potential treatment for schizophrenia.
Per the press release, the chronic, severe and disabling brain disorder, schizophrenia affects approximately 2.4 million adults in the U.S.
We note that the market for schizophrenia is highly competitive with the presence of drugs from large-cap pharma companies including Johnson & Johnson’s (JNJ - Free Report) Invega Sustenna and Risperdal Consta, and Allergan plc’s Vraylar. A few other companies are also developing their candidates for this indication.
Alkermes PLC Price and Consensus
Alkermes PLC Price and Consensus | Alkermes PLC Quote
Alkermes carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>